Azabicyclic heterocycles as cannabinoid receptor modulators

US7816357B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Guixue Yu · Wakefield, US
• William R. Ewing · Yardley, US
• Amarendra B. Mikkilineni · Easton, US
• Annapurna Pendri · South Glastonbury, US
• Bruce A. Ellsworth · Princeton, US
• Philip M. Sher · Plainsboro, US
• Samuel Gerritz · Guilford, US
• Chongqing Sun · Plainsboro, US
• Natesan Murugesan · Lawrenceville, US
• Ximao Wu · Princeton Junction, US

Key dates

• Filing date: Dec 17, 2004
• Grant date: Oct 19, 2010
• Expiry date: Aug 23, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I.including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein.